Webcast ImageWebcast
Adaptimmune to discuss updated data from 2018 ASCO annual meeting (Live)
06/04/18 at 8:00 a.m. ET
Adaptimmune to discuss updated data from 2018 ASCO annual meeting
Monday, June 4, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
05/16/18Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois. Data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS) will be presented during an oral presentation by Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center. G... 
Printer Friendly Version
05/09/18Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO -  - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORD, United Kingdom, May 09, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the f... 
Printer Friendly Version
04/25/18Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general business update before the open of the U.S. markets on Wednesday May 9, 2018. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day. The press release and the live webcast of the co... 
Printer Friendly Version
04/16/18Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
- Preclinical testing raises no safety concerns for MAGE A4 - - Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity - PHILADELPHIA, Pa. and OXFORD, United Kingdom, April 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the annual AACR meeting at McCormick Place in Chicago,... 
Printer Friendly Version
04/12/18Adaptimmune Announces Changes to Board of Directors
PHILADELPHIA, Pa. and OXFORD, U.K., April 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned transition, John Furey has been appointed as an independent Non-Executive Director, and Peter Thompson, M.D., Ph.D., will be stepping down from the Board. Both changes are effective from July 5, 2018. Mr. Furey will also succeed Dr. Thompson as a member of the Remuneration Committee. Dr. Thompson has se... 
Printer Friendly Version
04/06/18Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PHILADELPHIA, Pa. and OXFORD, U.K., April 06, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the upcoming AACR meeting at McCormick Place in Chicago, Illinois. Session, date, time, and location (for both posters): Session Category (Title): Clinical Research (Adoptive Cell Therapy 2) Date: Monday Apr 16, 2018 Tim... 
Printer Friendly Version
03/15/18Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing patients in MAGE-A4 “basket” study at 100 million cell dose level - - Guidance confirmed: funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT (12:00 p.m. GMT) - PHILADELPHIA and OXFORD, United Kingdom, March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ... 
Printer Friendly Version
03/15/18Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors PHILADELPHIA and OXFORD, U.K., March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported three partial responses (two confirmed and one to be confirmed), and one stable disease in the first four patients dosed with NY-ESO SPEAR T-cells in a second solid tumor: myxoid/ round cell liposarcoma (MRCLS).  Patients tolerated t... 
Printer Friendly Version
03/05/18Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018
PHILADELPHIA and OXFORD, United Kingdom, March 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2017 and provide a general business update before the open of the U.S. markets on Thursday March 15, 2018. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) on the same day at which time management w... 
Printer Friendly Version
01/08/18Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data from its two ongoing pilot studies of SPEAR T-cells targeting MAGE-A10, one in non-small cell lung cancer (NSCLC) and a triple tumor study in bladder, melanoma, and head & neck cancers. To date, 8 patients have each received 100 million transduced MAGE‑A10 SPEAR T-cells in the first dose coh... 
Printer Friendly Version
01/08/18Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company
Successful Manufacturing of SPEAR T-cells for a Patient at its Navy Yard Site and Agreement with Cell and Gene Therapy Catapult to Increase Vector Manufacturing Capacity PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has successfully manufactured the first SPEAR T-cells for a patient at its Navy Yard facility in Philadelphia. In addition, Adaptimmune anno... 
Printer Friendly Version
01/04/18Paul Stead Joins Adaptimmune as Vice President of Business Development
PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of Business Development. "I am delighted to welcome Paul to Adaptimmune. Paul has a tremendous wealth of business development experience and joins Adaptimmune at a critical inflection point in the Company’s journey, as we are focu... 
Printer Friendly Version